NEW YORK, Oct. 10 - Orchid BioSciences and Ellipsis Biotherapeutics have entered into a pharmacogenomics collaboration that will use Orchid’s SNPcode technology, the companies said on Wednesday.

Under the terms of the agreement Orchid will use its MegaSNPatron conduct high-throughput SNP-genotyping and construct high-density chromosome maps using clinical samples provided by Ellipsis. The partnership will initially study SNPs associated with inflammatory bowel disease, according to a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.